Current Report Filing (8-k)
17 December 2018 - 10:29PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 13, 2018
IMPRIMIS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35814
|
|
45-0567010
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
12264
El Camino Real, Suite 350
|
|
|
San
Diego, CA
|
|
92130
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 704-4040
|
N/A
|
|
|
(Former
name or former address if changed since last report.)
|
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.03 Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.
On
December 13, 2018, the board of directors of Imprimis Pharmaceuticals, Inc. (the “Company”) took action to start the
process by which the Company will change its name from “Imprimis Pharmaceuticals, Inc.” to “Harrow Health, Inc.”
The Delaware General Corporations Law permits the Company to change its name by board action without the approval of the stockholders
of the Company. It is anticipated that the name change will be completed within the next thirty days.
The
stockholders of the Company need not take any action in respect of the name change. Additionally, once the name change is completed,
stockholders do not need to exchange their certificates representing their shares of common stock. The current stock certificate
will continue to represent their ownership interest in the Company. Stockholders, however, may return their certificates to the
transfer agent for the Company after the name change is completed, and obtain an updated certificate with a new CUSIP number.
Item
7.01. Regulation FD Disclosure
Attached
as Exhibit 99.1 to this Item 7.01 is a presentation of the Company, that is being used by the management of the Company at investor
conferences and at meetings describing the Company.
The
information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item
9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Imprimis
Pharmaceuticals, Inc.
|
|
|
Date:
December 17, 2018
|
By:
|
/s/
Andrew R. Boll
|
|
Name:
|
Andrew
R. Boll
|
|
Title:
|
Chief
Financial Officer
|
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From May 2024 to Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ): 0 recent articles
More Imprimis Pharmaceuticals, Inc. News Articles